Pancreatic cancer is highly malignant, progresses rapidly and has a poor prognosis. Its survival is mainly related to the stage of pancreatic cancer, the site of the cancer and the type of pathology. The 5-year survival rate of pancreatic head cancer can reach 20%-30% after surgery, while the 5-year survival rate of pancreatic tail cancer is only 5%-15% even if radical surgery is performed to remove the cancer. In the current staging of pancreatic cancer, stage I and stage II are early stage pancreatic cancer and can be considered for radical surgical resection with relatively good prognosis. The surgical resection rate of early stage pancreatic cancer can reach 90%-100%, while the 5-year survival rate can reach 50%-70%, which is a significant improvement in survival compared with the progressive stage pancreatic cancer. The survival of advanced pancreatic cancer is usually no more than 1 year due to the inability of surgical or radical surgical resection. For patients who are unable to undergo surgical resection, death is likely to occur within 3 months. Since the pancreas is a retroperitoneal organ with a deep location, early clinical symptoms are not obvious and therefore difficult to diagnose and detect, which is one of the main reasons affecting the poor prognosis of pancreatic cancer at present.